{"filing":{"accession_number":"0001193125-26-266731","cik":"0001672619","ticker":"ELVN","company_name":"Enliven Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"d202685d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526266731/d202685d8k.htm"},"events":[{"id":5337,"run_id":4675,"accession_number":"0001193125-26-266731","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Enliven Therapeutics announced updated positive Phase 1 clinical trial data from the ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia, including key outcomes from an FDA End-of-Phase 1 meeting and selection of the 80 mg QD dose for Phase 3 development. This represents material clinical progress for the company's lead candidate that affects investor assessment of the pipeline and regulatory pathway.","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6103,"accession_number":"0001193125-26-266731","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces \"updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.\" This is a material clinical trial update for a biopharmaceutical company's lead candidate, which would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other enumerated event types), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:10:09.500663+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6104,"accession_number":"0001193125-26-266731","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces updated positive Phase 1 clinical trial data for ELVN-001 in CML patients and key outcomes from an FDA End-of-Phase 1 meeting, including selection of the 80 mg QD dose for Phase 3 development. While this is significant clinical progress for a development-stage biotech company, it does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The announcement of clinical trial results and regulatory feedback is material to investors assessing the company's pipeline advancement, but lacks the terminal or structural significance of restatements, going-concern issues, or M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:10:09.500663+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6103,"accession_number":"0001193125-26-266731","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces \"updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.\" This is a material clinical trial update for a biopharmaceutical company's lead candidate, which would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other enumerated event types), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:10:09.500663+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-11"},{"id":6104,"accession_number":"0001193125-26-266731","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces updated positive Phase 1 clinical trial data for ELVN-001 in CML patients and key outcomes from an FDA End-of-Phase 1 meeting, including selection of the 80 mg QD dose for Phase 3 development. While this is significant clinical progress for a development-stage biotech company, it does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The announcement of clinical trial results and regulatory feedback is material to investors assessing the company's pipeline advancement, but lacks the terminal or structural significance of restatements, going-concern issues, or M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:10:09.500663+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-11"}]}